EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baseline Hemoglobin and Outcomes in Advanced Chronic Kidney Disease with Moderate-to-Severe Myocardial Ischemia: A Secondary Analysis of the ISCHEMIA-CKD Trial

Anar Mammadli, Erdem Diker

Journal of Clinical Medicine · 05.11.2026 · 15 (21) · 8610

DOI: 10.3390/jcm15218610 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Anar Mammadli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Acıbadem Bayındır Söğütözü Hospital, Ankara 06250, Türkiye. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Hemoglobin may identify differences in prognosis among patients with advanced chronic kidney disease (CKD) and documented myocardial ischemia. We examined the shape of its association with clinical outcomes in ISCHEMIA-CKD.

Methods

This exploratory observational secondary analysis included 758 randomized participants with baseline hemoglobin. The primary endpoint was the parent-trial composite of all-cause death or myocardial infarction (MI). Adjusted Cox regression with restricted cubic splines characterized the hemoglobin association. Mortality and pooled nonfatal MI were examined using Cox and competing-risk models.

Results

Median hemoglobin was 11.1 g/dL; 247 participants experienced the primary endpoint. The adjusted association departed from log-linearity (p = 0.015), with higher hazard at lower hemoglobin and an uncertain upper limb. Relative to 11.1 g/dL, the hazard ratio (HR) at 8 g/dL was 1.98 (95% confidence interval [CI] 1.26–3.10). As a linear summary, the HR per 1 g/dL lower hemoglobin was 1.13 (95% CI 1.04–1.23) for the primary endpoint. Corresponding mortality associations were present, whereas pooled nonfatal MI showed no clear association (subdistribution HR 1.03, 95% CI 0.89–1.21). Exploratory treatment interaction tests provided no convincing evidence of effect modification (linear p = 0.059; spline p = 0.124).

Conclusions

Among selected, clinically stable participants with advanced CKD and moderate-to-severe ischemia, lower baseline hemoglobin was associated with adverse prognosis. Nonlinearity and uncertainty at higher values argue against a single summary estimate or an inferred optimal target. These potentially confounded findings neither establish benefit from hemoglobin correction nor support hemoglobin-based selection of invasive versus conservative management.

Schlagwörter

Stichwörter der Autor:innen

anemiachronic kidney diseasehemoglobinmyocardial ischemiaprognosis

Autor:innen und Institutionen

  • Department of Cardiology, Acıbadem Bayındır Söğütözü Hospital, Ankara 06250, Türkiye.
  • Department of Cardiology, School of Medicine, Ankara Medipol University, Ankara 06050, Türkiye.

Zitieren

APA

Mammadli, A., & Diker, E. (2026). Baseline Hemoglobin and Outcomes in Advanced Chronic Kidney Disease with Moderate-to-Severe Myocardial Ischemia: A Secondary Analysis of the ISCHEMIA-CKD Trial. Journal of Clinical Medicine, 15(21), 8610. https://doi.org/10.3390/jcm15218610

Vancouver

Mammadli A, Diker E. Baseline Hemoglobin and Outcomes in Advanced Chronic Kidney Disease with Moderate-to-Severe Myocardial Ischemia: A Secondary Analysis of the ISCHEMIA-CKD Trial. Journal of Clinical Medicine. 2026;15(21):8610. doi:10.3390/jcm15218610

BibTeX
@article{Mammadli2026,
  author = {Mammadli, Anar and Diker, Erdem},
  title = {Baseline Hemoglobin and Outcomes in Advanced Chronic Kidney Disease with Moderate-to-Severe Myocardial Ischemia: A Secondary Analysis of the ISCHEMIA-CKD Trial},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {8610},
  doi = {10.3390/jcm15218610}
}
Kostenlos starten →